These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11998892)

  • 1. The IL-2/IL-15 receptor systems: targets for immunotherapy.
    Waldmann TA
    J Clin Immunol; 2002 Mar; 22(2):51-6. PubMed ID: 11998892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.
    Waldmann T
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S161-7. PubMed ID: 12110135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biology and immunotherapy advance of interleukin 2 and interleukin 15-review].
    Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1088-92. PubMed ID: 19698267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.
    Waldmann TA
    Cancer Immunol Res; 2015 Mar; 3(3):219-27. PubMed ID: 25736261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 signaling and the maintenance of self-tolerance.
    Nelson BH
    Curr Dir Autoimmun; 2002; 5():92-112. PubMed ID: 11826762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases.
    Waldmann TA
    Arthritis Res Ther; 2004; 6(4):174-7. PubMed ID: 15225362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth.
    Rao BM; Driver I; Lauffenburger DA; Wittrup KD
    Biochemistry; 2005 Aug; 44(31):10696-701. PubMed ID: 16060678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.
    Morris JC; Janik JE; White JD; Fleisher TA; Brown M; Tsudo M; Goldman CK; Bryant B; Petrus M; Top L; Lee CC; Gao W; Waldmann TA
    Proc Natl Acad Sci U S A; 2006 Jan; 103(2):401-6. PubMed ID: 16387851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.
    Waldmann TA
    J Natl Cancer Inst; 1989 Jun; 81(12):914-23. PubMed ID: 2659803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
    Waldmann TA; Dubois S; Tagaya Y
    Immunity; 2001 Feb; 14(2):105-10. PubMed ID: 11239443
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphokine receptor-directed therapy: a model of immune intervention.
    Waldmann TA; Grant A; Tendler C; Greenberg S; Goldman C; Bamford R; Junghans RP; Nelson D
    J Clin Immunol; 1990 Nov; 10(6 Suppl):19S-28S; discussion 28S-29S. PubMed ID: 2081786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.
    Waldmann TA
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S28-30. PubMed ID: 24326545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection.
    Baan CC; van Gelder T; Balk AH; Knoop CJ; Holweg CT; Maat LP; Weimar W
    Transplantation; 2000 Feb; 69(3):331-6. PubMed ID: 10706038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes.
    Pillet AH; Thèze J; Rose T
    Hum Immunol; 2011 Nov; 72(11):1013-7. PubMed ID: 21925225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative cell-based ELISA, for a humanized anti-IL-2/IL-15 receptor beta antibody (HuMikbeta(1)), and correlation with functional activity using an antigen-transfected murine cell line.
    Yang XY; Chen E; Jiang H; Hartmann WK; Mitra G; Hecht T; Soman G
    J Immunol Methods; 2006 Apr; 311(1-2):71-80. PubMed ID: 16564055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
    Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW
    Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671
    [No Abstract]   [Full Text] [Related]  

  • 19. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
    Waldmann TA
    Nat Rev Immunol; 2006 Aug; 6(8):595-601. PubMed ID: 16868550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-15 in the life and death of lymphocytes: immunotherapeutic implications.
    Waldmann TA
    Trends Mol Med; 2003 Dec; 9(12):517-21. PubMed ID: 14659465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.